Persistence in patients with breast cancer treated with tamoxifen or aromatase inhibitors: a retrospective database analysis
- 20 January 2013
- journal article
- Published by Springer Science and Business Media LLC in Breast Cancer Research and Treatment
- Vol. 138 (1), 185-191
- https://doi.org/10.1007/s10549-013-2417-1
Abstract
No abstract availableKeywords
This publication has 36 references indexed in Scilit:
- American Society of Clinical Oncology Clinical Practice Guideline: Update on Adjuvant Endocrine Therapy for Women With Hormone Receptor–Positive Breast CancerJournal of Clinical Oncology, 2010
- Estimates of cancer incidence and mortality in Europe in 2008European Journal of Cancer, 2010
- Clinical perspectives on the utility of aromatase inhibitors for the adjuvant treatment of breast cancerThe Breast, 2009
- Breast CancerJournal of the National Comprehensive Cancer Network, 2009
- Menopausal symptoms and adjuvant therapy-associated adverse eventsEndocrine-Related Cancer, 2008
- Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trialThe Lancet Oncology, 2008
- Summary of aromatase inhibitor clinical trials in postmenopausal women with early breast cancerCancer, 2007
- Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trialsThe Lancet, 2005
- ATAC trial updateThe Lancet, 2005
- Adherence to Therapy With Oral Antineoplastic AgentsJNCI Journal of the National Cancer Institute, 2002